<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653740</url>
  </required_header>
  <id_info>
    <org_study_id>OMERIC-1904</org_study_id>
    <nct_id>NCT04653740</nct_id>
  </id_info>
  <brief_title>Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer</brief_title>
  <acronym>OMERIC</acronym>
  <official_title>Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC): A Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire PRISM - Michel SALZET</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric cohort study, prospective and interventional with minimal risks and&#xD;
      constraints for advanced breast cancer. The planned interventions are collection of&#xD;
      biological samples at different times. The study will aim to do a descriptive analysis of&#xD;
      omics profiles evolution (tumor, volatile organic components) over time, before and after&#xD;
      disease progression under Palbociclib treatment with a clinical-biological database.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in the study will receive the following interventions:&#xD;
&#xD;
        -  Biospecimen sample collection: before and during treatment, and at progression&#xD;
&#xD;
        -  Tumor biopsy before treatment and at progression&#xD;
&#xD;
      The aim of this study is to describe molecular changes associated with resistance to&#xD;
      Palbociclib at the individual level and describe longitudinal changes in the profile of&#xD;
      tumor, VOCs and exosomes according to treatment response.&#xD;
&#xD;
      Other objectives of the study include:&#xD;
&#xD;
        -  Proportion of single or shared molecular alterations / signatures between patients at&#xD;
           progression time&#xD;
&#xD;
        -  Associations between tumor signatures, VOCs and exosomes&#xD;
&#xD;
        -  Compare molecular changes identified by proteomics with those observed by genomics /&#xD;
           transcriptomics&#xD;
&#xD;
        -  Compare the evolution of VOCs and exosomes over time with evolution of liquid biopsy&#xD;
           markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrapatient variation in molecular profiles at progression compared to baseline</measure>
    <time_frame>From date of inclusion until the date of first documented progression (around 2 years)</time_frame>
    <description>Variation over time in the rate of VOCs in response to treatment and in progression situations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>longitudinal changes in VOCs profile and exosomes according to response to treatment</measure>
    <time_frame>From date of inclusion until the date of first documented progression, assessed up to 2 years</time_frame>
    <description>variation over time in exosomes count in response to treatment and in progression situations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of alterations / molecular signatures unique or shared between patients at progression</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Frequency of molecular alterations in the population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between tumor signatures, VOCs and exosomes</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Distribution of VOCs and exosome profiles according to the different molecular profiles of tumors that will be identified</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Concordance between molecular changes identified by proteomics and those observed by genomics/transcriptomics</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Concordance between identified proteins and expressed genes and/or detected mutations</description>
  </other_outcome>
  <other_outcome>
    <measure>Describe the evolution of VOCs and exosomes over time in relation to the evolution of liquid biopsy markers (CA15.3)</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Intra-patient variation over time in VOC rate (rate of CA15.3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Describe the evolution of VOCs and exosomes over time in relation to the evolution of liquid biopsy markers (CA15.3)</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Intra-patient variation over time in exosomes count (rate of CA15.3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Describe the evolution of VOCs and exosomes over time in relation to the evolution of liquid biopsy markers (CA15.3)</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Intra-patient variation over time in liquid biopsy markers (rate of CA15.3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Describe the evolution of VOCs and exosomes over time in relation to the evolution of liquid biopsy markers (LDH)</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Intra-patient variation over time in VOC rate (rate of LDH)</description>
  </other_outcome>
  <other_outcome>
    <measure>Describe the evolution of VOCs and exosomes over time in relation to the evolution of liquid biopsy markers (LDH)</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Intra-patient variation over time in exosomes count (rate of LDH)</description>
  </other_outcome>
  <other_outcome>
    <measure>Describe the evolution of VOCs and exosomes over time in relation to the evolution of liquid biopsy markers (LDH)</measure>
    <time_frame>At progression time, up to 2 years</time_frame>
    <description>Intra-patient variation over time in liquid biopsy markers (rate of LDH)</description>
  </other_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>specimen sample collection</intervention_name>
    <description>Before and during treatment, and at progression, collection of :&#xD;
Blood&#xD;
Exhaled air&#xD;
Saliva&#xD;
Sweat&#xD;
Tears&#xD;
Urine</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women over 18 years old&#xD;
&#xD;
          -  With histologically proven breast cancer, positives hormones receptors and negative&#xD;
             HER2&#xD;
&#xD;
          -  Advanced disease (metastases or non-resequable locoregional disease), from the 1st to&#xD;
             the 4th line.&#xD;
&#xD;
          -  With an indication for hormone therapy associated with the CDK4/6 inhibitor&#xD;
             Palbociclib&#xD;
&#xD;
          -  Agree to the sampling of the study&#xD;
&#xD;
          -  Signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neoadjuvant or adjuvant treatment for localized breast cancer&#xD;
&#xD;
          -  Metastatic breast cancer beyond the forth line&#xD;
&#xD;
          -  Impossibility to give informed consent (person deprived of liberty or under&#xD;
             guardianship)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female with breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nawale NH HAJJAJI, MD, PhD</last_name>
    <phone>0320295910</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie MV VANSEYMORTIER, MD, PhD</last_name>
    <phone>0320295910</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nawale NH HAJJAJI, MD, PhD</last_name>
      <phone>0320295910</phone>
      <email>promotion@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Nawale NH Hajjaji, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte CB Bellier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie EK Kaczmarek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey AM Maillez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>omics profiles</keyword>
  <keyword>proteomics</keyword>
  <keyword>volatile organic compounds</keyword>
  <keyword>exosomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

